French Government Intervenes in Doliprane Ownership Amid Worker Strikes
Sanofi's decision to sell 50% of its Doliprane-producing subsidiary to an American fund has sparked political uproar and worker strikes, prompting state investment and negotiations to secure jobs and production in France.
- Sanofi plans to sell 50% of its Opella subsidiary, which produces Doliprane, to the American investment fund CD&R.
- The French government, through Bpifrance, will invest between 100 and 150 million euros to maintain a 1-2% stake in Opella, ensuring the drug remains under French influence.
- Worker strikes have erupted at Sanofi sites, with significant actions at Lisieux and support from other locations, amid concerns over job security and production continuity.
- An agreement between the government, Sanofi, and CD&R includes commitments to keep production sites and jobs in France, with penalties for non-compliance.
- The deal, expected to finalize by mid-2025, aims to balance foreign investment with national interests, retaining key operations and governance in France.
Marianne 
Le Point 
l'Opinion 
Courrier International 